TY - JOUR T1 - Multifocal breast cancers are more prevalent in <em>BRCA2</em> versus <em>BRCA1</em> mutation carriers JF - medRxiv DO - 10.1101/19006478 SP - 19006478 AU - Alan David McCrorie AU - Susannah Ashfield AU - Colin Mcilmunn AU - Patrick J. Morrison AU - Clinton Boyd AU - Kienan I. Savage AU - Stuart Andrew McIntosh Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/09/13/19006478.abstract N2 - Multifocal breast cancer is generally considered to be where two or more breast tumours are present within the same breast, but are clearly separated with no intervening in situ or invasive disease. It is seen in ∼10% of breast cancer cases. This study investigates multifocality prevalence in BRCA1/2 mutant patients via cross-sectional analysis. Data from 211 women with BRCA1/2 mutations (BRCA1 - 91), (BRCA2 - 120), with breast cancer were collected including age, tumour focality, size, type, grade, and receptor profile. The prevalence of multifocality within this group was 25%, but within subgroups, prevalence amongst BRCA2 carriers was more than double that of BRCA1 carriers (p=0.001). Women affected by multifocal tumours had proportionately higher oestrogen receptor positivity (p=0.001), lower triple negativity (p=0.004), and were more likely to be younger at diagnosis compared with those with unifocal tumours (p=0.039). Odds of a BRCA2 carrier developing multifocal cancer were almost four-fold higher than a BRCA1 carrier (OR: 3.71, CI: 1.77-7.78, p=0.001). BRCA2 carriers show much greater multifocality than those carrying BRCA1 – multifocal tumours are strongly associated with being both BRCA2 mutant and oestrogen receptor positive.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was obtained to support this project.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableData referred to in the manuscript is not publically available as it derives from patient pathology notes and records which are directly identifiable. ER -